Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes
NCT00318786
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
289
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetes
Diabetes Mellitus, Type 2
Interventions
DRUG:
biphasic insulin aspart
Sponsor
Novo Nordisk A/S